SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts

Experts in implant retrieval, biomaterials and clinical practice examine the science, clinical experience and potential advantages of silicon nitride relative to established implant materials in Company-sponsored Orthopedics This Week Masterclass

SALT LAKE CITY, Utah, Sept. 14, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced the availability of a Company-sponsored Masterclass hosted by Orthopedics This Week (“OTW”), the most widely read publication in the orthopedics industry, that brings together three industry experts to present arguments examining the value of silicon nitride over legacy implant materials and to increase awareness of the impact it may have in orthopedic applications.

“SINTX is a global innovator in the type of materials discussed by the orthopedics experts in the Masterclass presentation, including silicon nitride components and biocomposites,” remarked Eric Olson, Chairman and CEO of SINTX Technologies. “In addition to our existing legacy business providing silicon nitride solutions for industrial applications, we believe that the unique properties of the material presented in the Masterclass, combined with SINTX’s patents, proprietary manufacturing processes, and SiNERGY™ platform technology will contribute to SINTX’s position as a leader in this exciting space.”

SINTX has developed proprietary expertise in the processing, manufacturing, and application of silicon nitride and is working to expand the material’s use across multiple orthopedic markets. The Company is pursuing opportunities to expand the use of silicon nitride across spine, foot and ankle, and other orthopedic markets as it continues its transition from a biomaterials technology company toward a commercially focused medical device organization.

This includes the Company’s SiNERGY biocomposite platform, which leverages the inherently antibacterial nature of silicon nitride to optimize sutures, mesh, wound dressings, and other textile-based applications.

The Masterclass, titled “Silicon Nitride in Orthopedics,” explores the science behind medical-grade silicon nitride, clinical experience with the material, and how certain properties of the material, including its surface chemistry and reported bone-cell response have been evaluated relative to established orthopedic implant materials such as PEEK and titanium. The discussion provides surgeons, researchers, distributors, investors and other industry participants with perspectives from experts whose work spans implant retrieval, biomaterials research and clinical practice. They also discuss potential future applications for silicon nitride in composite and 3D printing applications.

“Education is an important part of introducing innovative biomaterials to the orthopedic community,” said Ryan Elmore, President of SINTX Technologies. “We are pleased to work with Orthopedics This Week to provide surgeons and other orthopedic professionals with an opportunity to learn more about the science behind silicon nitride and its potential role in the future of orthopedic care. With more than 400,000 annual readers in over 120 countries, OTW provides an excellent platform for reaching a highly relevant and engaged audience of orthopedic professionals and industry participants for SINTX innovations.”

Click here to register for the Silicon Nitride in Orthopedics Masterclass on Orthopedics This Week.

About SINTX Technologies, Inc.

Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities, and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SiNAPTIC^® Foot & Ankle Osteotomy Implant System for reconstructive surgery.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding the potential impact and future role of silicon nitride in orthopedic applications; potential future applications in composites, additive manufacturing and bearing surfaces; SINTX's efforts and ability to expand silicon nitride into additional orthopedic markets; the Company's continued transition toward a commercially focused medical-device business; and the expectation that the Company's intellectual property, manufacturing capabilities and material attributes may strengthen its competitive position. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the Company's ability to successfully develop and commercialize its products and technologies; obtain and maintain applicable regulatory clearances or approvals; achieve market acceptance among surgeons, healthcare providers, distributors and other customers; substantiate anticipated product characteristics and performance; protect and enforce its intellectual property; manufacture products at commercial scale; and successfully execute its strategic and commercial objectives, as well as those described in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other SEC filings. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update any forward-looking statement, except as required by applicable law.

Company Contact:
Andrew Benson
SINTX Technologies, Inc.
801.839.3504
IR@sintx.com